Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Generate Biomedicines, Inc.NASDAQ: GENB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development of $54.56M in Q1 FY2026

Q1 FY2026 research & development was $54.56M.

Context

  • Research & development amounted to 704.5% of revenue in FY2025, down 152.4 pp from a year earlier.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$54.56M— QoQ
Last fiscal yearDec 2025
$224.7M+28.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+28.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
224.7M USD
Year-over-year change
+28.2%
1-year CAGR
+28.2%

Research & Development vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 research & development of $224.7M is the highest of the 5 companies compared; the peer median is $126.11M.
  • Its year-over-year change of +28.2% is the highest of 5, against a peer median of -18.4%.
  • Research & development amounts to 704.5% of revenue for GENB, versus a peer median of 2433.8%.
GENB Competitors Peer median
Research & Development for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GENBGenerate Biomedicines, Inc.FY2025$224.7M +28.2%—704.5%
ABCLAbCellera Biologics Inc.LTM Sep 2026$186.28M +1.9%+20.1%274.5%
STROSutro Biopharma, Inc.LTM Mar 2026$151.37M -38.7%+6.7%152.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$100.84M -42.7%+0.9%7756.8%
ABSIAbsci CorporationLTM Mar 2026$84.33M +24.0%+11.4%4593.1%
Peer median (excluding GENB) $126.11M-18.4%+9.0%2433.8%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.46M31.89M
Cost of Revenue00
Gross Profit20.46M31.89M
Gross Margin100.0%100.0%
Research & Development175.31M224.7M
Selling, General & Admin42.09M42.26M
Operating Expenses217.4M266.96M
Depreciation & Amortization15.35M13.18M
EBITDA(163.71M)(208.49M)
EBITDA Margin-800.2%-653.7%
Operating Income(196.94M)(235.07M)
Operating Margin-962.6%-737.0%
Interest Income18.12M13.66M
Interest Expense2.12M1.14M
Other Income / Expenses15.77M12.26M
Income Before Tax(181.17M)(222.8M)
Pre-Tax Margin-885.5%-698.6%
Income Tax Expense212K163K
Net Income(173.77M)(203.15M)
Net Margin-849.4%-637.0%
EPS (Basic)(1.68)(4.98)
EPS (Diluted)(1.68)(4.98)
Weighted Avg Shares127.45M50.09M
Weighted Avg Shares (Diluted)127.45M50.09M

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.